Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Afimetoran, a Toll‐Like Receptor 7 and 8 Inhibitor, in Patients With Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double‐Blind, Placebo‐Controlled Study

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Afimetoran, a Toll‐Like Receptor 7 and 8 Inhibitor, in Patients With Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double‐Blind, Placebo‐Controlled Study

Objective There is an unmet need for safe and effective oral treatments for cutaneous lupus erythematosus (CLE). Afimetoran is an investigational, first‐in‐class, orally bioavailable, selective small molecule inhibitor of Toll‐like receptors (TLRs) 7 and 8. We investigated the safety, tolerability,...

Full description

Saved in:
Bibliographic Details
Main Authors: Fareeda Hosein, Stanislav Ignatenko, Kristina D. Chadwick, Lin Zhu, Frédéric Baribaud, Jasmine Saini, Thanh Bach, Urvi Aras, WanYing Zhang, Hazem Karabeber, Michelle Dawes, Melanie Harrison, Leonidas N. Carayannopoulos, Gopal Krishna
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.70059
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/acr2.70059

Similar Items